Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer

28 Sept 2021

Abstract excerpt

A precise predictive biomarker for TNBC response to immunochemotherapy is urgently needed. We previously established a 27-gene IO signature for TNBC derived from a previously established 101-gene model for classifying TNBC. Here we report a pilot study to assess the performance of a 27-gene IO signature in predicting the pCR of TNBC to preoperative immunochemotherapy. We obtained RNA sequencing data from the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Cancer Immunotherapy and Biomarkers
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34638323
DOI: 10.3390/cancers13194839

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast CancerPMID 34638323Read ↗

The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast CancerSemantic proximity Read ↗

Translation of the 27-gene immuno-oncology test (IO Score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patientsSemantic proximity Read ↗

Construction and validation of a gene expression classifier to predict immunotherapy response in primary triple-negative breast cancerSemantic proximity Read ↗

Immune Milieu and Genomic Alterations Set the Triple-Negative Breast Cancer Immunomodulatory Subtype Tumor BehaviorSemantic proximity Read ↗

An Immune-Related Gene Prognostic Index for Triple-Negative Breast Cancer Integrates Multiple Aspects of Tumor-Immune MicroenvironmentSemantic proximity Read ↗

Classification of triple-negative breast cancers based on Immunogenomic profilingSemantic proximity Read ↗

A 10-Gene Signature to Predict the Prognosis of Early-Stage Triple-Negative Breast CancerSemantic proximity Read ↗

A Novel Immune Checkpoint-Related Gene Signature to Predict Overall Survival and Immunotherapy Response in Triple-Negative Breast CancerSemantic proximity Read ↗

Machine learning models based on immunological genes to predict the response to neoadjuvant therapy in breast cancer patientsSemantic proximity Read ↗

Identification of a Gene Panel Predictive of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy Employing Transcriptomic and Functional ValidationSemantic proximity Read ↗

Genomic and transcriptomic analyses identify distinctive features of triple-negative inflammatory breast cancerSemantic proximity Read ↗

Development and validation of a stromal immune phenotype classifier for predicting immune activity and prognosis in triple-negative breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.